Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
Molecular Partners reports progress in its lead Radio-DARPin MP0712 with a Phase 1/2a study underway in multiple US clinical sites and initial data expected in 2026. The company unveiled an isotope-agnostic Radio-DARPin strategy enabling flexible therapeutic payloads and strengthened its financial position with CHF 79 million cash, supporting pipel…